



Commercial/Healthcare Exchange PA Criteria

Effective: August 2017

Prior Authorization: Steroid Inhalers

Products Affected: Alvesco (ciclesonide) oral inhalation; ArmonAir RespiClick (fluticasone propionate) oral inhalation

Medication Description: Ciclesonide is a non-halogenated glucocorticoid which is beneficial in treating inflammatory conditions such as allergic rhinitis and asthma. Fluticasone oral inhalation products are used for the maintenance treatment of asthma. Orally inhaled corticosteroids (ICS) are considered a preferred pharmacologic treatment in the long-term management of persistent asthma.

Covered Uses: Maintenance treatment of asthma as prophylactic therapy

Exclusion Criteria: Status asthmaticus or other acute episodes of asthma

Required Medical Information:

1. Diagnosis
2. Previous medications tried/failed

Age Restrictions: 12 years of age and older

Prescriber Restrictions: N/A

Coverage Duration: 12 months

Other Criteria:

Alvesco:

For Healthcare Exchange members only:

- A. Patient has a diagnosis of Asthma; AND
- B. Patient has had a documented trial and failure of at least TWO of the following medications:
 - Asmanex
 - Flovent
 - Arnuity Ellipta
 - Pulmicort

ArmonAir:

For Commercial and Healthcare Exchange members:

- A. Patient has a diagnosis of Asthma; AND
- B. Patient has had a documented trial and failure of at least TWO of the following medications:
 - Asmanex
 - Flovent
 - Arnuity Ellipta
 - Pulmicort

Last Res.1.13.2020



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.

References:

1. Alvesco (ciclesonide) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals; March 2018.
2. Product Information: ARMONAIR(TM) RESPICLICK(R) inhalation powder, fluticasone propionate inhalation powder. Teva Respiratory, LLC (per manufacturer), Frazer, PA, 2017.

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	8/2017
2	Update	Removed affected products from CCI Inhalers Policy and created Steroid Inhalers Policy; Adopted EH template specified criteria; CCI P&T Review History: 8/17, 11/17, 11/18; CCI Revision Record: 11/17	All	1/13/2020